AstraZeneca
In Brief This Week: AstraZeneca, Daiichi Sankyo, Turning Point, Recursion, Cleveland Clinic
News items for the week of Oct. 4, 2021.
AstraZeneca Begins TIGIT/PD-1 Antibody Study in NSCLC, Triggering Milestone Payment for Compugen
The company is exploring the bispecific antibody's activity in advanced NSCLC patients and also considering their response according to tumor PD-L1 expression.
European Society for Medical Oncology Congress 2021: Precision Oncology Data Roundup
Researchers presented data at the meeting on biomarker-directed therapies and tests to characterize patients' responses to cancer treatment.Â
Experts Consider Resistance, Combinations as Another HER2-Targeted Breast Cancer Drug Emerges
Byondis' trastuzumab duocarmazine improved progression-free survival compared to physicians' choice of treatment for metastatic HER2-positive breast cancer patients in a Phase III trial.
ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu
Premium
Studies showed that the antibody-drug conjugate benefited HER2-mutated NSCLC patients and outperformed Genentech's T-DM1 in HER2-positive, previously treated breast cancer.